Dahuang Zhechong pills inhibit liver cancer growth in a mouse model by reversing Treg/Th1 balance.
10.1016/S1875-5364(22)60160-2
- Author:
Tian-Tian CHEN
1
;
Sha-Li DU
1
;
Shi-Jun WANG
2
;
Li WU
3
;
Lu YIN
4
Author Information
1. Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
2. Shandong Co-innovation Center of TCM Formula, School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
3. Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China. Electronic address: wuli@njucm.edu.cn.
4. Shandong Co-innovation Center of TCM Formula, School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China. Electronic address: profyinlu@163.com.
- Publication Type:Journal Article
- Keywords:
Balance;
Dahuang Zhechong pill;
Hepatocellular;
Network pharmacology;
Th1-Treg
- MeSH:
Animals;
CD8-Positive T-Lymphocytes;
Carcinoma, Hepatocellular/drug therapy*;
Drugs, Chinese Herbal;
Humans;
Liver Neoplasms/drug therapy*;
Mice;
T-Lymphocytes, Regulatory;
Tumor Microenvironment
- From:
Chinese Journal of Natural Medicines (English Ed.)
2022;20(2):102-110
- CountryChina
- Language:English
-
Abstract:
The infiltration of immune cells into the hepatocellular carcinoma microenvironment is the main reason why hepatocellular carcinoma patients are prone to carcinoma recurrence and the disease are incurable. Notably, the infiltration of Treg cells is the main trigger. Dahuang Zhechong pill (DHZCP) is a traditional Chinese herbal compound successful in the treatment of hepatitis and hepatocellular carcinoma. DHZCP can heal and nourish while slowing the onset of the disease, thereby strengthening the body's immune function. It can localize tumors and ultimately achieve the goal of eliminating tumors. In this study, an orthotopic liver cancer model of mice was used to explore the mechanism of DHZCP enhancing anti-tumor immunity, which showed more Th1 cells in the peripheral blood and spleen after DHZCP treatment, while more IFN-γ was secreted to activate CD8+ T cells and Treg cell production was inhibited, thereby suppressing the growth of HCC. Finally, we also analyzed the potential components of DHZCP from the perspective of modern targets using network pharmacology methods and experimental results.
